Related Experiment Video
Updated: Apr 15, 2026

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.1K
Unsupervised Sparse Multi-Task Learning With Application to Alzheimer's Disease
Hao Chen1, Jiadong Ji2, Dong Liu3
1Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Statistics in Medicine
|April 14, 2026
Summary
Researchers developed SMART, a new method to identify Alzheimer's disease (AD) biomarkers from brain imaging. SMART improves accuracy and interpretability for AD progression studies.
Area of Science:
- Neuroscience
- Biostatistics
- Medical Imaging
Background:
- Alzheimer's disease (AD) progression is challenging to track using high-dimensional fMRI data.
- Identifying interpretable brain functional connectivity biomarkers is crucial for understanding AD.
- Existing methods struggle with high dimensionality, disease-stage heterogeneity, and collinearity in fMRI data.
Purpose of the Study:
- To propose a unified statistical method, Sparse Multi-task Adaptive Regularization Truncation (SMART), for identifying AD biomarkers.
- To address challenges of high dimensionality, disease-stage heterogeneity, and connection collinearity in fMRI data.
- To enhance the accuracy, stability, and interpretability of biomarker identification for AD progression.
Main Methods:
- Developed SMART, a method incorporating L1-penalty for sparsity, L2-penalty for stable activation patterns, and a truncated L2-penalty (TLP) for adaptive grouping.
- Utilized a DC-ADMM algorithm for efficient computation and convergence to KKT points.
- Validated SMART through comprehensive simulation studies and real-data analysis of AD neuroimaging data.
Main Results:
- SMART demonstrated superior accuracy in identifying functional connectivity biomarkers for AD.
- The method showed enhanced stability in feature selection across different disease stages.
- SMART improved the interpretability of biomarkers for AD cohort studies.
Conclusions:
- SMART provides a robust and interpretable framework for identifying brain functional connectivity biomarkers in Alzheimer's disease.
- The method effectively handles the complexities of high-dimensional fMRI data, offering advantages over existing approaches.
- The accompanying R package facilitates the application of SMART in AD research.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

